Patricia Fernandez
Publicacions destacades
-
Understanding the microenvironment contribution to ductal carcinoma in situ transition to invasiveness in breast cancer
Autors:Referència: CANCER RESEARCH. -
Differential expression of neurogenes among breast cancer subtypes identifies high risk patients
Autors:Referència: ONCOTARGET. -
Substance P Autocrine Signaling Contributes to Persistent HER2 Activation That Drives Malignant Progression and Drug Resistance in Breast Cancer
Autors:Referència: CANCER RESEARCH. -
A methodology for the isolation, culture, and immortalization of human breast epithelial and myoepithelial cells.
Autors:Referència: MOLECULAR CANCER THERAPEUTICS. -
The New Antitumor Drug ABTL0812 Inhibits the Akt/mTORC1 Axis by Upregulating Tribbles-3 Pseudokinase
Autors:Referència: CLINICAL CANCER RESEARCH. -
Subtype specific expression of HRH1 contributes to increased chemoresistance of breast cancer cells
Autors:Referència: MOLECULAR CANCER RESEARCH. -
Targeting of substance P induces cancer cell death and decreases the steady state of EGFR and Her2
Autors:Referència: JOURNAL OF CELLULAR PHYSIOLOGY. -
Tumor promoting effects of CD95 signaling in chemoresistant cells
Autors:Referència: MOLECULAR CANCER. -
Histamine receptor 1 inhibition enhances antitumor therapeutic responses through extracellular signal-regulated kinase (ERK) activation in breast cancer
Autors:Referència: CANCER LETTERS.